Olfactive Detection of Urothelial Carcinoma by Sniffer Dogs

NCT07334314 | Recruiting

• 1 other identifier: 9630
• Study Type: observational
• Target: 340
• Locations: 1 country
• Sites: 2

Brief Summary

The aim of this study is to estimate the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained in this practice.

Conditions

Urothelial Carcinoma

Outcome Measures

Primary Outcomes (1)

• Assess the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained for this purpose

  Day -60 to Day 0

Study Arms (2)

Positive bladder tumor

Bladder tumor present during cystoscopy and confirmed by pathological examination.

Diagnostic Test: olfactory detection by dogs

Negative bladder tumor

No bladder tumor on cystoscopy/suspicious lesion but with negative pathological analysis

Diagnostic Test: olfactory detection by dogs

Interventions

olfactory detection by dogs DIAGNOSTIC_TEST

olfactory detection of urothelial carcinoma of the bladder in a urine sample by dogs

Negative bladder tumor; Positive bladder tumor

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subject scheduled for any endourological surgery involving an initial cystoscopy, the most common of which are: transurethral resection of the bladder, transurethral resection of the prostate, internal optical urethrotomy, bladder lithoclast, ureteral stent replacement, ureteroscopy, etc. (non-exhaustive list). Recruitment will take place in the urology department, during the preoperative consultation or during hospitalization.

You may qualify if:

• Adult (\> 18 years old)
• Subject scheduled for any endourological surgery involving an initial cystoscopy, the most common of which are: transurethral resection of the bladder, transurethral resection of the prostate, internal optical urethrotomy, bladder lithoclast, ureteral stent replacement, ureteroscopy, etc. (non-exhaustive list)
• Subjects for whom a urine sample (for bacteriological or cytological testing) is planned as part of routine practice in the month prior to the procedure
• Subjects affiliated with a health insurance plan or beneficiaries of such a plan

You may not qualify if:

• Absence of signed informed consent / inability to provide the subject with informed information (emergency situations, difficulties in understanding the subject, etc.)
• Patient under guardianship, conservatorship, or judicial protection
• History of cancer other than urothelial bladder carcinoma, unless in complete remission for \> 5 years
• Pregnant or breastfeeding women

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (2)

Hôpitaux Civils de Colmar

Colmar, France

RECRUITING

Hôpitaux Universitaires de Strasbourg

Strasbourg, France

RECRUITING

MeSH Terms

Conditions

Carcinoma, Transitional Cell

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Central Study Contacts

Victor GAILLARD

CONTACT

+33 3 69 55 10 55; victor.gaillard@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 10, 2025
• First Posted: January 12, 2026
• Study Start: June 20, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: January 12, 2026

Record last verified: 2025-12

Locations

FR (2)